drugset / Trial / NCT00237666

Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression

NCT00237666

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the antidepressant effectiveness of Geodon for the treatment of patients diagnosed with Bipolar II disorder who are currently experiencing a major depressive episode.

Timeline

Start
2005-02
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ziprasidone Small molecule 20 mg Oral
Subject Ziprasidone Small molecule 60 mg Oral